Company Overview: Asterias Biotherapeutics

Industry News

2 Oct

Asterias Announces Two Significant Developments for Spinal Cord Injury Program

67% of Cohort 2 subjects have recovered two or more motor levels on at least one side through 12 months AST-OPC1 receives Regenerative Medicine Advanced Therapy (RMAT) designation from FDA FREMONT, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company pioneering the field...

Read more

26 Sep

Asterias Receives Regulatory Clearance to Initiate Clinical Study of AST-VAC2 in Subjects with Early and Late Stage Non-Small Cell Lung Cancer

FREMONT, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) and the NHS Research Ethics Committee (REC) have provided the necessary approvals to initiate the first-in-human...

Read more

6 Sep

Asterias Biotherapeutics to Present at Upcoming Conferences

FREMONT, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that members of the Company’s management team will be presenting at two upcoming investor conferences in September: Rodman & Renshaw Annual Global Investment Conference on Monday,...

Read more

23 Aug

Asterias Biotherapeutics Opens Additional Clinical Site for AST-OPC1 SCiStar Study

FREMONT, Calif., Aug. 23, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Washington University School of Medicine in St. Louis, MO, has been added as a clinical site in the company’s ongoing SCiStar Phase 1/2a clinical...

Read more

14 Aug

Asterias Announces Major AST-VAC2 Development Milestone: First cGMP-Compliant Lot Successfully Manufactured to Support First Clinical Study of AST-VAC2

FREMONT, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Cancer Research UK, supported by Asterias technical personnel, has successfully completed manufacture of the first cGMP (current Good Manufacturing Practice) clinical grade lot of...

Read more

9 Aug

Asterias Enrolls First Patient in Final Cohort of SCiStar Clinical Trial

FREMONT, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) — Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced enrollment and dosing of the first patient in the fifth and final cohort in the company’s ongoing SCiStar Phase 1/2a clinical study of AST-OPC1 in...

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address